Equities research analysts expect DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) to post ($0.16) earnings per share for the current quarter, Zacks reports. Zero analysts have made estimates for DelMar Pharmaceuticals’ earnings. DelMar Pharmaceuticals posted earnings per share of ($0.13) in the same quarter last year, which would indicate a negative year over year growth rate of 23.1%. The business is scheduled to issue its next quarterly earnings report on Friday, February 9th.
On average, analysts expect that DelMar Pharmaceuticals will report full year earnings of ($0.61) per share for the current year, with EPS estimates ranging from ($0.65) to ($0.57). For the next financial year, analysts forecast that the company will post earnings of ($0.26) per share. Zacks’ EPS calculations are a mean average based on a survey of analysts that that provide coverage for DelMar Pharmaceuticals.
DMPI has been the topic of a number of recent analyst reports. Maxim Group downgraded DelMar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, August 14th. Dawson James reiterated a “buy” rating on shares of DelMar Pharmaceuticals in a research report on Tuesday, August 8th. Finally, HC Wainwright reiterated a “buy” rating and set a $12.00 price target on shares of DelMar Pharmaceuticals in a research report on Thursday, October 5th.
Shares of DelMar Pharmaceuticals (NASDAQ:DMPI) traded down $0.03 during mid-day trading on Friday, reaching $0.81. The company’s stock had a trading volume of 534,300 shares, compared to its average volume of 377,704. DelMar Pharmaceuticals has a 52 week low of $0.78 and a 52 week high of $5.39.
An institutional investor recently bought a new position in DelMar Pharmaceuticals stock. Sabby Management LLC bought a new stake in DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 645,390 shares of the company’s stock, valued at approximately $1,484,000. Sabby Management LLC owned approximately 4.79% of DelMar Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 8.23% of the company’s stock.
DelMar Pharmaceuticals Company Profile
DelMar Pharmaceuticals, Inc is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DelMar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.